Person: BAYRAKLI, FATİH
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
BAYRAKLI
First Name
FATİH
Name
4 results
Search Results
Now showing 1 - 4 of 4
Publication Open Access Pilocytic Astrocytoma of the Cerebellopontine Angle with cerebrospinal fluid Spread in an Adult: A Case Report(2022-12-01) KURŞUN, MELTEM; OĞUZSOY, TUBA; BOZKURT, SÜHEYLA; BAYRAKLI, FATİH; BIYIKLI, ERHAN; Bıyıklı E., Kurşun M., Oğuzsoy T., Bozkurt S., Bayraklı F.Introduction Pilocytic astrocytoma of the cerebellopontine angle (CPA) is uncommon, and its spread to the cerebrospinal fluid (CSF) at the time of diagnosis has not been reported in the literature. Case Presentation We report the case of a 33-year-old man with multifocal pilocytic astrocytoma diagnosed by magnetic resonance imaging (MRI) and confirmed by histopathological examination, and present the radiological and histopathological findings. Conclusion In the case herein reported, we observed spread of the pilocytic astrocytoma of the CPA to the CSF at the initial diagnosis, and early detection by MRI is very important regarding the treatment modality and prognosis.Publication Metadata only Past, present, and future of therapies for pituitary neuroendocrine tumors: need for omics and drug repositioning guidance(2022-03-01) ERDOĞAN, ONUR; ARĞA, KAZIM YALÇIN; BOZKURT, SÜHEYLA; BAYRAKLI, FATİH; YILMAZ, BETÜL; TURANLI, BESTE; Aydin B., Yildirim E., ERDOĞAN O., ARĞA K. Y., Yilmaz B., BOZKURT S., BAYRAKLI F., TURANLI B.Innovation roadmaps are important, because they encourage the actors in an innovation ecosystem to creatively imagine multiple possible science future(s), while anticipating the prospects and challenges on the innovation trajectory. In this overarching context, this expert review highlights the present unmet need for therapeutic innovations for pituitary neuroendocrine tumors (PitNETs), also known as pituitary adenomas. Although there are many drugs used in practice to treat PitNETs, many of these drugs can have negative side effects and show highly variable outcomes in terms of overall recovery. Building innovation roadmaps for PitNETs\" treatments can allow incorporation of systems biology approaches to bring about insights at multiple levels of cell biology, from genes to proteins to metabolites. Using the systems biology techniques, it will then be possible to offer potential therapeutic strategies for the convergence of preventive approaches and patient-centered disease treatment. Here, we first provide a comprehensive overview of the molecular subtypes of PitNETs and therapeutics for these tumors from the past to the present. We then discuss examples of clinical trials and drug repositioning studies and how multi-omics studies can help in discovery and rational development of new therapeutics for PitNETs. Finally, this expert review offers new public health and personalized medicine approaches on cases that are refractory to conventional treatment or recur despite currently used surgical and/or drug therapy.Publication Metadata only Decoding molecular signatures of pituitary neuroendocrine tumors’ subtypes through systems biomedicine perspective(2021-12-21) BAYRAKLI, FATİH; BOZKURT, SÜHEYLA; ARĞA, KAZIM YALÇIN; TURANLI, BESTE; AYDIN B., Yildirim Sirkeci E., ERDOĞAN O., BAYRAKLI F., BOZKURT S., ARĞA K. Y., TURANLI B.Publication Metadata only Low grade oligodendroglioma seeding around the 4th ventricle(Taylor and Francis Ltd, 2019) BAYRAKLI, FATİH; Erdogan O., Sakar M., Bozkurt S., Bayrakli F.We report a 45 years old female patient with a left temporal grade II oligodendroglioma that recurred on the wall of the fourth ventricle at grade II oligodendroglioma. © 2019, © 2019 The Neurosurgical Foundation.